Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

SUZHOU, China, April 26, 2024 /PRNewswire/ -- Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a grou...

2024-04-26 21:00 710

Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers

* The second DMC review recommends the continuation of dose escalation in the clinical trial as per protocol. * The interim safety assessment was based on the review of safety data from 18 metastatic gastrointestinal cancer patients, including patients that have tolerated multiple doses of ca...

2024-04-26 21:00 714

Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa

SHANGHAI, April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year onApril 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger...

2024-04-26 12:39 746

Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints

* CBL-514 is the first product to treat cellulite at the raised areas. * Currently, there is no effective and safe cellulite treatment on the market. The global market for cellulite treatment is estimated to expand to $7.37 billion in 2034. * CBL-0201EFP Phase 2 study demonstrated CBL-514 sta...

2024-04-26 01:25 840

2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor

SHANGHAI, April 25, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented in an ...

2024-04-25 22:00 728

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Biosc...

2024-04-25 21:41 890

On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference

* miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1% * African authority on malaria diagnosis said "miLab is a potential game changer in accelerating access to parasitological confirmation" YONGIN, South Korea, April 25,...

2024-04-25 21:00 983

On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

* The only solution for intractable cancer caused by mutations in the p53 gene * Planning clinical trials targeting cancer patients with no available treatment due to p53 gene mutations SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced onApril 25th that its clinica...

2024-04-25 17:11 799

PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono

PRISM BioLab will utilize PepMetics®, innovative small molecules that mimic three-dimensional structures of alpha-helix and beta-turns of peptidesfor drug discoveryagainst oncology target selected by Ono TOKYO, April 25, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery ...

2024-04-25 14:00 656

ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST

SUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the co...

2024-04-25 09:02 898

Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting

Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference. SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new med...

2024-04-24 22:10 1035

Future Health highlights greater access to treatment for Mental Health Month

SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- A recent poll has highlighted an alarming trend: a staggering 90% of Americans feel we are in a mental health crisis. While Mental Health Month in May seeks to build ...

2024-04-24 22:00 798

Future Health highlights greater access to treatment for Mental Health Month

Meihua International Medical Technologies Co., Ltd. Reports 2023 Financial Year Results

YANGZHOU, China, April 24, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today reported its financial ...

2024-04-24 19:00 1384

Samsung Biologics Reports First Quarter 2024 Financial Results

* Recorded Q1'24 consolidated revenue of KRW 946.9 billion * Recorded Q1'24 consolidated operating profit of KRW 221.3 billion * Sustained growth driven by ongoing strategic expansion in capacity and portfolio INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 20794...

2024-04-24 14:45 952

Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)

Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO:Jae...

2024-04-24 09:27 858

OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market

SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical ...

2024-04-23 18:37 1177

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)

SAN DIEGO and WUHAN, China, April 23, 2024 /PRNewswire/ -- HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the N...

2024-04-23 14:54 920

Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing

SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately$20 million. This Pre-A round is led by Shunxi F...

2024-04-23 08:00 892

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

* Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024 DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therap...

2024-04-23 07:25 1373

Datasea Inc. (NASDAQ: DTSS) and iPower Inc. (NASDAQ: IPW) Collaborate to Expand Product Distribution in US Online Markets

BEIJING, April 22, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a trailblazing digital technology company incorporated in Nevada, dedicated to innovative solutions in acoustic high tech and 5G-Artificial Intelligence ("AI") multimodal communication technology inth...

2024-04-22 22:00 940

12 3 4 5 ... 195